vs

Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and GERMAN AMERICAN BANCORP, INC. (GABC). Click either name above to swap in a different company.

GERMAN AMERICAN BANCORP, INC. is the larger business by last-quarter revenue ($126.7M vs $85.1M, roughly 1.5× 4D Molecular Therapeutics, Inc.). GERMAN AMERICAN BANCORP, INC. runs the higher net margin — 28.2% vs 22.8%, a 5.4% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 39.7%). GERMAN AMERICAN BANCORP, INC. produced more free cash flow last quarter ($154.0M vs $28.5M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 22.7%).

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

American Express Company or Amex is an American bank holding company and multinational financial services corporation that specializes in payment cards. It is headquartered at 200 Vesey Street, also known as American Express Tower, in the Battery Park City neighborhood of Lower Manhattan.

FDMT vs GABC — Head-to-Head

Bigger by revenue
GABC
GABC
1.5× larger
GABC
$126.7M
$85.1M
FDMT
Growing faster (revenue YoY)
FDMT
FDMT
+8508860.3% gap
FDMT
8508900.0%
39.7%
GABC
Higher net margin
GABC
GABC
5.4% more per $
GABC
28.2%
22.8%
FDMT
More free cash flow
GABC
GABC
$125.5M more FCF
GABC
$154.0M
$28.5M
FDMT
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
22.7%
GABC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FDMT
FDMT
GABC
GABC
Revenue
$85.1M
$126.7M
Net Profit
$19.4M
$35.7M
Gross Margin
Operating Margin
17.3%
34.6%
Net Margin
22.8%
28.2%
Revenue YoY
8508900.0%
39.7%
Net Profit YoY
139.1%
53.7%
EPS (diluted)
$0.43
$0.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FDMT
FDMT
GABC
GABC
Q4 25
$85.1M
$126.7M
Q3 25
$90.0K
$126.5M
Q2 25
$15.0K
$123.2M
Q1 25
$14.0K
$111.1M
Q4 24
$1.0K
$90.7M
Q3 24
$3.0K
$88.5M
Q2 24
$5.0K
$90.5M
Q1 24
$28.0K
$84.1M
Net Profit
FDMT
FDMT
GABC
GABC
Q4 25
$19.4M
$35.7M
Q3 25
$-56.9M
$35.1M
Q2 25
$-54.7M
$31.4M
Q1 25
$-48.0M
$10.5M
Q4 24
$23.2M
Q3 24
$-43.8M
$21.0M
Q2 24
$-35.0M
$20.5M
Q1 24
$-32.4M
$19.0M
Operating Margin
FDMT
FDMT
GABC
GABC
Q4 25
17.3%
34.6%
Q3 25
-67983.3%
34.6%
Q2 25
-396373.3%
31.8%
Q1 25
-383007.1%
12.0%
Q4 24
31.6%
Q3 24
-1704400.0%
29.0%
Q2 24
-849120.0%
29.4%
Q1 24
-136200.0%
27.6%
Net Margin
FDMT
FDMT
GABC
GABC
Q4 25
22.8%
28.2%
Q3 25
-63195.6%
27.7%
Q2 25
-364386.7%
25.5%
Q1 25
-342657.1%
9.5%
Q4 24
25.6%
Q3 24
-1461433.3%
23.8%
Q2 24
-699060.0%
22.7%
Q1 24
-115717.9%
22.6%
EPS (diluted)
FDMT
FDMT
GABC
GABC
Q4 25
$0.43
$0.98
Q3 25
$-1.01
$0.94
Q2 25
$-0.98
$0.84
Q1 25
$-0.86
$0.30
Q4 24
$0.79
Q3 24
$-0.79
$0.71
Q2 24
$-0.63
$0.69
Q1 24
$-0.66
$0.64

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FDMT
FDMT
GABC
GABC
Cash + ST InvestmentsLiquidity on hand
$402.7M
Total DebtLower is stronger
$100.0M
Stockholders' EquityBook value
$505.7M
$1.2B
Total Assets
$566.7M
$8.4B
Debt / EquityLower = less leverage
0.09×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FDMT
FDMT
GABC
GABC
Q4 25
$402.7M
Q3 25
$305.1M
Q2 25
$293.2M
Q1 25
$321.4M
Q4 24
$424.9M
Q3 24
$501.9M
Q2 24
$541.9M
Q1 24
$525.9M
Total Debt
FDMT
FDMT
GABC
GABC
Q4 25
$100.0M
Q3 25
Q2 25
Q1 25
Q4 24
$114.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
FDMT
FDMT
GABC
GABC
Q4 25
$505.7M
$1.2B
Q3 25
$369.0M
$1.1B
Q2 25
$420.9M
$1.1B
Q1 25
$469.7M
$1.0B
Q4 24
$510.6M
$715.1M
Q3 24
$552.9M
$744.6M
Q2 24
$588.3M
$687.8M
Q1 24
$600.6M
$655.3M
Total Assets
FDMT
FDMT
GABC
GABC
Q4 25
$566.7M
$8.4B
Q3 25
$424.0M
$8.4B
Q2 25
$473.6M
$8.3B
Q1 25
$515.7M
$8.4B
Q4 24
$560.4M
$6.3B
Q3 24
$604.0M
$6.3B
Q2 24
$620.1M
$6.2B
Q1 24
$629.9M
$6.1B
Debt / Equity
FDMT
FDMT
GABC
GABC
Q4 25
0.09×
Q3 25
Q2 25
Q1 25
Q4 24
0.16×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FDMT
FDMT
GABC
GABC
Operating Cash FlowLast quarter
$28.6M
$159.3M
Free Cash FlowOCF − Capex
$28.5M
$154.0M
FCF MarginFCF / Revenue
33.5%
121.6%
Capex IntensityCapex / Revenue
0.1%
4.2%
Cash ConversionOCF / Net Profit
1.47×
4.46×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M
$267.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FDMT
FDMT
GABC
GABC
Q4 25
$28.6M
$159.3M
Q3 25
$-46.5M
$51.8M
Q2 25
$-43.4M
$26.9M
Q1 25
$-47.8M
$37.9M
Q4 24
$-134.6M
$95.8M
Q3 24
$-29.4M
$24.5M
Q2 24
$-30.2M
$18.7M
Q1 24
$-29.1M
$23.9M
Free Cash Flow
FDMT
FDMT
GABC
GABC
Q4 25
$28.5M
$154.0M
Q3 25
$-46.6M
$50.1M
Q2 25
$-43.4M
$26.2M
Q1 25
$-48.4M
$36.7M
Q4 24
$-138.4M
$90.7M
Q3 24
$-31.2M
$23.0M
Q2 24
$-30.6M
$17.0M
Q1 24
$-29.8M
$22.6M
FCF Margin
FDMT
FDMT
GABC
GABC
Q4 25
33.5%
121.6%
Q3 25
-51765.6%
39.6%
Q2 25
-289620.0%
21.2%
Q1 25
-345635.7%
33.0%
Q4 24
-13837100.0%
100.1%
Q3 24
-1038966.7%
26.0%
Q2 24
-611840.0%
18.8%
Q1 24
-106421.4%
26.9%
Capex Intensity
FDMT
FDMT
GABC
GABC
Q4 25
0.1%
4.2%
Q3 25
101.1%
1.3%
Q2 25
440.0%
0.6%
Q1 25
4507.1%
1.1%
Q4 24
378600.0%
5.6%
Q3 24
59266.7%
1.7%
Q2 24
6980.0%
1.8%
Q1 24
2535.7%
1.5%
Cash Conversion
FDMT
FDMT
GABC
GABC
Q4 25
1.47×
4.46×
Q3 25
1.48×
Q2 25
0.86×
Q1 25
3.61×
Q4 24
4.13×
Q3 24
1.16×
Q2 24
0.91×
Q1 24
1.25×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons